Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.57 |
| ▸ | ESR1 | P03372 | 11/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29596744 | 0.91 | CRBN (0.56) | CRBNESR1IKZF2IKZF3CSNK1A1 | |
| SCHEMBL30903884 | 0.91 | CRBN (0.63) | CRBNESR1IKZF2IKZF3CSNK1A1 | |
| SCHEMBL29596415 | 0.87 | CRBN (0.56) | CRBNESR1 | |
| SCHEMBL22661482 | 0.87 | CRBN (0.53) | CRBNESR1IKZF2CSNK1A1 | |
| SCHEMBL22661387 | 0.86 | CRBN (0.58) | CRBNESR1IKZF2IKZF3CSNK1A1 | |
| SCHEMBL29597401 | 0.85 | CRBN (0.56) | CRBNESR1IKZF2IKZF3CSNK1A1 | |
| SCHEMBL20046361 | 0.85 | CRBN (0.66) | CRBNESR1IKZF2CSNK1A1 | |
| SCHEMBL30903867 | 0.84 | CRBN (0.56) | CRBNESR1IKZF2IKZF3 | |
| SCHEMBL30984796 | 0.84 | CRBN (0.64) | CRBNESR1IKZF2 | |
| SCHEMBL30906253 | 0.83 | CRBN (0.63) | CRBNESR1IKZF2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4089083-A1 | PIPERIDINE-2,6-DIONE SUBSTITUTED ISOINDOLES IN THE PREPARATION OF SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | Accutar Biotechnology Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11312702-B2 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312702-B2 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | AR, NR5A1, ESRRA | CRBN 357/4885ESR1 13/4885IKZF2 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.